EUS-guided FNA diagnostic yield of malignancy in solid pancreatic masses: a benchmark for quality performance measurement

Thomas J. Savides, Michael Donohue, Gordon Hunt, Mohammed Al-Haddad, Harry Aslanian, Tamir Ben-Menachem, Victor K. Chen, Coyle Walter Coyle, John Deutsch, John DeWitt, Manish Dhawan, Alexander Eckardt, Mohamad Eloubeidi, Alec Esker, Stuart R. Gordon, Frank Gress, Steven Ikenberry, Ann Marie Joyce, Jason Klapman, Simon LoFauze Maluf-Filho, Nicholas Nickl, Virmeet Singh, Jason Wills, Cynthia Behling

Research output: Contribution to journalArticle

123 Scopus citations

Abstract

Background: The diagnostic yield of EUS-guided FNA (EUS-FNA) of solid pancreatic masses is a potential benchmark for EUS-FNA quality, because the majority of EUS-FNA of solid pancreatic masses should be diagnostic for malignancy. Objectives: To determine the cytologic diagnostic rate of malignancy in EUS-FNA of solid pancreatic masses and to determine if variability exists among endoscopists and centers. Design: Multicenter retrospective study. Patients: EUS centers provided cytology reports for all EUS-FNAs of solid, noncystic, ≥10-mm-diameter, solid pancreatic masses during a 1-year period. Main Outcome Measurement: Cytology diagnostic of pancreatic malignancy. Results: A total of 1075 patients underwent EUS-FNA at 21 centers (81% academic) with 41 endoscopists. The median number of EUS-FNA of solid pancreatic masses performed during the year per center was 46 (range, 4-177) and per endoscopist was 19 (range, 1-97). The mean mass dimensions were 32 × 27 mm, with 73% located in the head. The mean number of passes was 3.5. Of the centers, 90% used immediate cytologic evaluation. The overall diagnostic rate of malignancy was 71%, 95% confidence interval 0.69%-0.74%, with 5% suspicious for malignancy, 6% atypical cells, and 18% negative for malignancy. The median diagnostic rate per center was 78% (range, 39%-93%; 1st quartile, 61%) and per endoscopist was 75% (range, 0%-100%; 1st quartile, 52%). Limitations: Retrospective study, participation bias, and varying chronic pancreatitis prevalence. Conclusions: (1) EUS-FNA cytology was diagnostic of malignancy in 71% of solid pancreatic masses and (2) endoscopists with a final cytologic diagnosis rate of malignancy for EUS-FNA of solid masses that was less than 52% were in the lowest quartile and should evaluate reasons for their low yield.

Original languageEnglish (US)
Pages (from-to)277-282
Number of pages6
JournalGastrointestinal endoscopy
Volume66
Issue number2
DOIs
StatePublished - Aug 1 2007
Externally publishedYes

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Gastroenterology

Fingerprint Dive into the research topics of 'EUS-guided FNA diagnostic yield of malignancy in solid pancreatic masses: a benchmark for quality performance measurement'. Together they form a unique fingerprint.

  • Cite this

    Savides, T. J., Donohue, M., Hunt, G., Al-Haddad, M., Aslanian, H., Ben-Menachem, T., Chen, V. K., Walter Coyle, C., Deutsch, J., DeWitt, J., Dhawan, M., Eckardt, A., Eloubeidi, M., Esker, A., Gordon, S. R., Gress, F., Ikenberry, S., Joyce, A. M., Klapman, J., ... Behling, C. (2007). EUS-guided FNA diagnostic yield of malignancy in solid pancreatic masses: a benchmark for quality performance measurement. Gastrointestinal endoscopy, 66(2), 277-282. https://doi.org/10.1016/j.gie.2007.01.017